<PAGE>

                                   SIGNATURES
             CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY

I, Earl L. Yager, as Chief Financial Officer of CHAD Therapeutics, Inc. (the
"Company"), hereby certify, pursuant to Rule 13a-14 (17 CFR 240.13a-14), that:

(1)      I have reviewed this quarterly report on Form 10-Q of CHAD
         Therapeutics, Inc.;

(2)      Based on my knowledge, this quarterly report does not contain any
         untrue statement of a material fact or omit to state a material fact
         necessary to make the statements made, in light of the circumstances
         under which such statements were made, not misleading with respect to
         the period covered by this quarterly report;

(3)      Based on my knowledge, the financial statements, and other financial
         information included in this quarterly report, fairly present in all
         material respects the financial condition, results of operations and
         cash flows of the registrant as of, and for, the periods presented in
         this quarterly report;

(4)      The registrant's other certifying officers and I are responsible for
         establishing and maintaining disclosure controls and procedures (as
         defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
         registrant and have:

         (a)  designed such disclosure controls and procedures, or caused
              such disclosure controls and procedures to be designed under
              our supervision, to ensure that material information relating
              to the registrant, including its consolidated subsidiaries, is
              made known to us by others within those entities, particularly
              during the period in which this quarterly report is being
              prepared;

         (b)  evaluated the effectiveness of the registrant's disclosure
              controls and procedures and presented in this report our
              conclusions about the effectiveness of the disclosure controls
              and procedures, as of the end of the period covered by this
              report based on such evaluation; and

         (c)  disclosed in this report any change in the registrant's
              internal control over financial reporting that occurred during
              the registrant's most recent fiscal quarter (the registrant's
              fourth fiscal quarter in the case of an annual report) that
              has materially affected, or is reasonably likely to materially
              affect the registrant's internal control over financial
              reporting; and

(5)      The registrant's other certifying officers and I have disclosed, based
         on our most recent evaluation of internal control over financial
         reporting, to the registrant's auditors and the audit committee of
         registrant's board of directors (or persons performing the equivalent
         functions):

         (a)  all significant deficiencies and material weaknesses in the
              design or operation of internal control over financial
              reporting which are reasonably likely to adversely affect the
              registrant's ability to record, process, summarize and report
              financial information; and

         (b)  any fraud, whether or not material, that involves management
              or other employees who have a significant role in the
              registrant's internal control over financial reporting.

Date: October 31, 2003        /S/ Earl L. Yager
                              --------------------------------------------------
                              Earl L. Yager
                              Chief Financial Officer of CHAD Therapeutics, Inc.